Skip to Content
Merck
CN
All Photos(3)

Documents

O7125

Sigma-Aldrich

L-Ornithine L-aspartate salt

≥98% (TLC)

Sign Into View Organizational & Contract Pricing
All Photos(3)
Synonym(s):
(S)-2,5-Diaminopentanoic acid L-aspartate salt
Empirical Formula (Hill Notation):
C9H19N3O6
CAS Number:
3230-94-2
Molecular Weight:
265.26
EC Number:
221-772-7
MDL number:
MFCD00058084
UNSPSC Code:
12352209
PubChem Substance ID:
329818920
NACRES:
NA.26

Assay

≥98% (TLC)

Quality Level

200

form

powder

color

white to off-white

storage temp.

2-8°C

SMILES string

NCCC[C@H](N)C(O)=O.N[C@@H](CC(O)=O)C(O)=O

InChI

1S/C5H12N2O2.C4H7NO4/c6-3-1-2-4(7)5(8)9;5-2(4(8)9)1-3(6)7/h4H,1-3,6-7H2,(H,8,9);2H,1,5H2,(H,6,7)(H,8,9)/t4-;2-/m00/s1

InChI key

IXUZXIMQZIMPSQ-ZBRNBAAYSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

Biochem/physiol Actions

L-Ornithine L-aspartate is a metabolite of arginine degradation by arginase. It has been shown to reduce blood ammonia concentrations by increasing ammoniadetoxification in the muscle and reducing the severity of hepatic encephalopathy in cirrhosis.

Other Notes

Product of arginine degradation by arginase

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Janus P Ong et al.
Clinical drug investigation, 31(4), 213-220 (2011-01-07)
Hepatic encephalopathy (HE) is a serious complication of cirrhosis. Clinical trials have consistently shown that L-ornithine-L-aspartate significantly improves HE symptoms. Health-related quality of life (HR-QOL) is impaired in HE patients and represents an important outcome measure for therapeutic intervention. The
Qian Jiang et al.
Journal of gastroenterology and hepatology, 24(1), 9-14 (2008-10-01)
Hepatic encephalopathy continues to be a major clinical problem and the current decade has not witnessed major therapeutic breakthroughs in this area. L-ornithine-l-aspartate (LOLA) is not frequently used as there are still some reservations about its benefits. The present study
Bin Zhang et al.
Bioresource technology, 284, 204-213 (2019-04-03)
l-ornithine, an important amino acid, is widely used in food and medicine industries. l-ornithine production mainly relies on microbial fermentation, which may not meet the industrial requirement owing to the poor fermentation ability of available strains. Herein, mscCG2 deletion, CgS9114_12202
Vibhu Vibhas Mittal et al.
European journal of gastroenterology & hepatology, 23(8), 725-732 (2011-06-08)
Minimal hepatic encephalopathy (MHE) impairs daily functioning and health-related quality of life (HRQoL). The modalities of treatment of MHE have not been adequately studied. To compare lactulose, probiotics, and L-ornithine L-aspartate (LOLA) in treatment of MHE and effect on HRQoL
Patrícia Coelho de Soárez et al.
Arquivos de gastroenterologia, 46(3), 241-247 (2009-11-18)
Experimental and clinical studies suggest that LOLA may have a favorable influence on hepatic encephalopathy due to the effect on the reduction of ammonia, and improvement of the symptoms and laboratory findings. To evaluate and to critically analyze the efficacy
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service